Kevin Kim, Md

This study is testing a drug called mirdametinib for people with advanced melanoma that has a specific genetic change (NF1 mutation) and has continued to grow despite standard immunotherapy. The main goals are to see if the drug is safe and if it can help control the cancer. It's…